ArticleFrontiers in human neuroscience2025
Case Report: When multiple system atrophy masquerades as CASPR2 autoimmune encephalopathy: a diagnostic pitfall.
Article in Frontiers in human neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Morvan syndrome in a patient with progressing metastatic thymoma and myasthenia gravis.BMJ case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Multiple system atrophy (MSA) is a sporadic, adult-onset neurodegenerative disorder characterized by rapid progression. Early diagnosis remains particularly challenging, especially when CASPR2 antibodies are detected during the early stages of disease progression. Case presentation: A 56-year-old female presented with chronic progressive cerebellar ataxia. Serum analysis revealed the presence of CASPR2 antibodies. Brain MRI demonstrated atrophy of the brainstem and cerebellum. The external anal-sphincter electromyography (EAS-EMG) indicated autonomic nerve dysfunction in the absence of overt clinical symptoms. Despite treatment with high-dose corticosteroids and immunosuppressants, no clinical improvement was observed. During follow-up, symptoms of autonomic nerve dysfunction emerged, leading to a clinical established diagnosis of cerebellar subtype of multiple system atrophy (MSA-C). Conclusion: In the early stages of MSA, autonomic nerve dysfunction may not manifest clinically. Therefore, close follow-up is essential for accurate diagnosis. EAS-EMG exhibits high sensitivity in detecting subclinical autonomic dysfunction. Although the co-occurrence of MSA-C and high-titer (1:100) CASPR2-IgG is uncommon, this case highlights the critical importance of relying on the overall clinical presentation, rather than on isolated laboratory findings, to establish the primary diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.